Login / Signup

Discontinuation of Direct Oral Anticoagulants in Response to Attorney Advertisements: Data From the FDA Adverse Event Reporting System.

Mohamed MohamoudSaharat PatanavanichPage CrewLynda McCulleyMonica MunozCindy KortepeterS Christopher JonesDaniel WoronowGerald Dal Pan
Published in: The Annals of pharmacotherapy (2019)
Keyphrases
  • direct oral anticoagulants
  • venous thromboembolism
  • adverse drug
  • atrial fibrillation
  • electronic health record
  • big data
  • data analysis
  • machine learning
  • artificial intelligence
  • drug induced